Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An ambispective, observational real-world study of tumor-treating fields for treatment of Chinese patients with newly diagnosed or recurrent/progressive glioblastoma.

Neuro-oncology advances·2026

Same author

MET fusions and splicing variants in glioma: a landscape integrating clinical, pathological, and survival features.

The journal of pathology. Clinical research·2026

Same author

A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations.

Cancer research·2026

Same author

Updated clinical practice guidelines for the management of adult diffuse gliomas.

Cancer letters·2025

Same author

Natural killer cell-specific chimeric antigen receptor enhances CAR NK cell functions and anti-tumor activity.

Theranostics·2025

Same author

Strategy and clinical benefit of first re-resection for recurrent adult-type diffuse glioma: A retrospective cohort analysis.

Med (New York, N.Y.)·2025

Search research articles

Related Experiment Video

Updated: Dec 31, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

CAR-armed cell therapy for gliomas.

You Zhai^1,2, Guanzhang Li^1,2, Tao Jiang^1,3,2,4,5

¹Beijing Neurosurgical Institute, Capital Medical University Beijing, China.

American Journal of Cancer Research

|January 9, 2020

Summary

Chimeric antigen receptor T cell (CAR-T) therapy shows promise for leukemia but faces challenges in treating solid tumors like glioma. Enhancing CAR-T cell targeting, regulation, and adaptation is key to improving glioma treatment outcomes.

Keywords:

CAR-T Glioma tumor microenvironment

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Dec 31, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

Oncology
Immunotherapy
Cell Therapy

Background:

Chimeric antigen receptor (CAR)-armed cell therapy has advanced significantly, particularly for leukemia treatment.
However, its efficacy against solid tumors, such as glioma, remains suboptimal.
This highlights a need to understand the unique challenges of CAR-T therapy in glioma compared to other malignancies.

Purpose of the Study:

To review current advancements and challenges in CAR-T therapy for glioma.
To explore strategies for enhancing CAR-T cell targeting, regulatory functions, and adaptability for solid tumors.
To identify potential solutions for overcoming obstacles in CAR-T treatment for glioma.

Main Methods:

Comprehensive review of clinical trials involving CAR-T therapy.
Analysis of preclinical animal experiments investigating CAR-T efficacy in glioma models.
Examination of design principles aimed at improving CAR-armed cell performance.

Main Results:

CAR-T therapy has demonstrated success in hematological malignancies but lags in solid tumor treatment.
Strategies to enhance CAR-T cell targeting, regulation, and adaptation are under investigation.
Animal studies provide insights into the potential of CAR-T therapy for glioma.

Conclusions:

Significant obstacles hinder the application of CAR-T therapy in glioma treatment.
Further research and innovative design approaches are necessary to improve CAR-T efficacy in gliomas.
Overcoming these challenges could pave the way for more effective CAR-T treatments for brain tumors.